Understanding Charcot Neuroarthropathy: Why Early Recognition Matters in the Diabetic Foot
Charcot neuro-osteoarthropathy (CNO), often called Charcot foot, is one of the most consequential — and most frequently missed — complications of long-standing diabetes. It is a progressive, non-infectious destruction of the bones and joints of the foot and ankle in a patient who has lost protective sensation due to peripheral neuropathy. Left unrecognized, an acute episode can collapse the midfoot in a matter of weeks, producing bony prominences, ulceration, deep infection, and ultimately limb loss. The 2023 International Working Group on the Diabetic Foot (IWGDF) guideline — the first dedicated to Charcot — has refocused clinical attention on early diagnosis, prompt offloading, and structured surveillance.
Scope of the Problem
Reported prevalence of Charcot in people with diabetes ranges from approximately 0.08% to 13%, with annual incidence estimates between 0.1% and 8%. The clinical stakes are high: a 2022 meta-analysis by Schmidt and Holmes in the Journal of Diabetes and Its Complications pooled 10 studies (871 feet) and reported an amputation frequency of 15% — 9% major and 5% minor — alongside a five-year mortality of roughly 24.5%. A 2023 cohort analysis by Bandeira and colleagues found that nearly 40% of patients with CN went on to develop a foot ulcer, and 15% required amputation.
Recognizing the Active Charcot Foot
The 2023 IWGDF guideline authored by Wukich and colleagues emphasizes a deceptively simple clinical rule: in any person with diabetes and peripheral neuropathy who presents with a warm, swollen, or red foot — particularly with intact skin and no other obvious explanation — active Charcot should be assumed until proven otherwise. The contralateral foot serves as a reference, and a temperature difference of more than approximately 2°C is highly suggestive. Infrared dermal thermometry, used in a standardized manner, is supported as a useful adjunct to track inflammation and treatment response over time.
The systematic review by Raspovic and colleagues (Diabetes/Metabolism Research and Reviews, 2024) that informed the guideline identified 37 eligible studies and concluded that plain radiographs may appear normal in early active CNO. Magnetic resonance imaging is the most sensitive modality for detecting subclinical bone marrow edema and stress injury, and is the imaging study of choice when initial films are unrevealing but clinical suspicion remains. Importantly, the guideline recommends against relying on C-reactive protein, erythrocyte sedimentation rate, white blood cell count, or alkaline phosphatase to confirm or exclude Charcot in the setting of intact skin — these biomarkers lack sufficient discriminatory power.
Offloading: The Cornerstone of Treatment
Once Charcot is suspected, knee-high immobilization should begin immediately, even before imaging is complete. The total contact cast (TCC) remains the reference standard. A 2021 retrospective cohort study by Wukich and colleagues in the Journal of Foot and Ankle Research reported a median TCC duration of approximately 4.3 months to achieve clinical resolution, with skin irritation (≈41%) and asymmetry pain (≈22%) as the most common complications. A 2024 pilot study published in Diabetes Care by Petrova and colleagues demonstrated that initiating offloading at stage 0 (the inflammatory pre-radiographic phase) significantly shortened TCC duration (median 75 vs. 111.5 days) and reduced both recurrence (2.7% vs. 9.7%) and the need for reconstructive surgery.
A 2024 systematic review in Foot and Ankle Surgery further suggested that protected weight-bearing during TCC does not appear to compromise healing, provided immobilization is rigorous and follow-up is frequent. Transition out of the cast — typically into a Charcot Restraint Orthotic Walker (CROW), then into accommodative footwear with custom orthoses — should be guided by clinical and thermometric resolution rather than by a fixed calendar.
Surgery and Long-Term Surveillance
Surgical reconstruction is reserved for feet with unstable deformity, recurrent ulceration over a bony prominence, or failed conservative management. A 2024 review in Frontiers in Clinical Diabetes and Healthcare outlined an evidence-based algorithm: midfoot exostectomy for limited prominences, and beam fixation or superconstruct techniques for global instability, with the goal of a plantigrade, ulcer-free foot that tolerates bracing. Even after remission, patients remain at lifelong risk of contralateral involvement and re-activation; long-term podiatric follow-up, custom footwear, and patient education about temperature self-monitoring are essential elements of secondary prevention.
Clinical Summary
Charcot neuroarthropathy is a time-sensitive diagnosis. The combination of a warm, swollen foot in a neuropathic patient with diabetes should trigger immediate offloading and advanced imaging when plain films are unremarkable. Early intervention — particularly at the stage 0 inflammatory phase — shortens treatment duration, reduces recurrence, and lowers the likelihood of reconstructive surgery or amputation. Total contact casting, infrared thermometry, and structured transition to definitive footwear together form the evidence-based backbone of contemporary care.
References
- Wukich DK, Raspovic KM, Hobizal KB, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3646.
- Raspovic KM, Hobizal KB, Rosenblum BI, et al. Diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus: A systematic review. Diabetes/Metabolism Research and Reviews. 2024;40(3):e3653.
- Schmidt BM, Holmes CM. Amputation and mortality frequencies associated with diabetic Charcot foot arthropathy: a meta-analysis. Journal of Diabetes and Its Complications. 2022;36(10):108296.
- Bandeira MA, dos Santos ALG, Woo K, Gamba MA, de Gouveia Santos VLC. Incidence and predictive factors for amputations derived from Charcot’s neuroarthropathy in persons with diabetes. The International Journal of Lower Extremity Wounds. 2023;22(3):542-549.
- Petrova NL, Donaldson NK, Bates M, et al. Charcot foot offloading in stage 0 is associated with shorter total contact cast treatment and lower risk of recurrence and reconstructive surgery: a pilot study. Diabetes Care. 2024;47(2):252-259.
- Pinzur MS, et al. Charcot neuro-osteoarthropathy: a review of key concepts and an evidence-based surgical management algorithm. Frontiers in Clinical Diabetes and Healthcare. 2024;5:1344359.
- Schaper NC, van Netten JJ, Apelqvist J, et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3657.
Comments
